

Original Article

The Prevalence of Common Mutations in Thrombophilic Patients in Iranian Population with Recurrent Miscarriage

Nasrin Pazoki¹ M.Sc., Farnosh Naseri^{2*} M.Sc

¹Department of Cell and Molecular Biology, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran.

²Department of Genetics, Faculty of Basic Sciences, East Tehran Branch, Islamic Azad University, Tehran, Iran.

ABSTRACT

Article history

Received 23 Jan 2018

Accepted 15 Jul 2018

Available online 31 May 2019

Key words

Mutation

Recurrent miscarriage

Thrombophilia

Background and Aims: To date, several factors have been reported in recurrent miscarriage. Genetic mutations are the most important causative factors in women. Fetal thrombotic vasculopathy is a new described placental alteration with varying degrees of involvement and often associated with adverse prenatal outcomes. The diagnosis is made histologically and so is postnatal, which makes it a challenge in clinical practice. The aim of the present study is investigation of the common mutations in women with recurrent miscarriage.

Materials and Methods: A cross-sectional study was conducted on 100 women with a history of recurrent miscarriage fetus in 2018. In these patients, several genes such as MTHFR, F2, F5 Leiden, PAI1, F13 and FGB were analyzed by sequencing techniques. The most common mutations in these genes were sequenced and analyzed.

Results: According to statistical results obtained, MTHFR gene (C677T, A1298C) has the highest rate (50 %) of common mutations ($p=0.001$). After that F2 (G20210A) and F5 Leiden (G1691A) have the highest statistical values (each one 20%). In addition to these genes, there are other unknown mutations which have not been studied in terms of pathogenicity. Other genes have a smaller percentage of aborted fetus infrequently.

Conclusions: Common polymorphisms in the thrombophilic system are likely to result in abortion in these subjects, due to impaired coagulation of the mother and the fetus. Investigating the presence of common mutations and examining their association with other mutations in the thrombophilia as a prognostic in patients with recurrent miscarriage is necessary.

*Corresponding Author: Department of Genetics, Faculty of Basic Sciences, East Tehran Branch, Islamic Azad University, Tehran, Iran. Tel: +982161192471; Email: Farnushnaseri@yahoo.com

Introduction

Thrombophilia is an abnormality of blood coagulation which can raise the risk of thrombosis (blood clots in blood vessels) [1]. Such abnormalities can be identified in 50% of people who have an episode of thrombosis (such as deep vein thrombosis in the leg) not provoked by other causes [2]. Fibrinogen, the precursor of fibrin and the end-product of blood coagulation, is an essential component of the hemostatic system [3]. Fibrinogen is converted to fibrin through limited proteolysis by thrombin which exposes polymerization sites to fibrin monomers [4]. Activated factor XIII forms covalent bonds between adjacent fibrin monomers. These cross-links strengthen the fibrin clot and increase its resistance to degradation by the fibrinolysis system [5]. There is no specific treatment for the thrombophilias, but recurrent episodes of thrombosis may be an indication for long term preventative anticoagulation [6]. The most common types of congenital thrombophilia are those that arise as a result of overactivity of coagulation factors. They are relatively mild and are therefore classified as (type 2) defects [7]. The most common types are factor 5 Leiden (a mutation in the F5 at position 1691) and prothrombin G20210A, a mutation in prothrombin (at position 20210 in the 3' untranslated region of the gene). Thromboembolic events occur as a result of disruption of the balance between fibrinolysis and thrombosis. Thus, it is important to examine the inherited and acquired thrombotic risk factors [8]. In the last five decades, the

molecular biases of both coagulation and anticoagulation pathways have been well studied and some hereditary risk factors have been found responsible for venous thromboembolism (VTE) [9]. F5 Leiden (FVL), Prothrombin gene (PT) and methylenetetrahydrofolate (MTHFR) polymorphism are the common molecular biomarkers used in the evaluation of tendency to venous thromboembolism [10]. The mutant F5 molecule is known as F5L and named as F5(R 506 Q) [11]. A single G allele was found as a nucleotide transition at position 20210 in the 3' untranslated region of the prothrombin gene in 18% of selected patients with familial venous thrombosis [12].

MTHFR enzyme plays a significant role in the cellular metabolism of folate and synthesis of nucleotides and is essential in the methyl cycle that converts homocysteine to methionine [13]. To date, two important MTHFR polymorphisms (C677T and A1298C) have been identified. These polymorphisms are related to reducing MTHFR activity [14]. The C677T mutation is known as a point mutation with the substitution of cysteine-thymine at the nucleotide position 677 of the MTHFR gene. Adverse pregnancy outcomes have recently been linked to inherited thrombophilias through extensive studies. However, conclusions regarding their association still remain inconsistent. Normal pregnancy is related with an acquired hypercoagulable state due to increased levels of coagulation factors, decreased levels of anticoagulants and decreased fibrinolytic activity. This

hypercoagulability may be intensified in women with heritable predisposition to thrombosis, known as thrombophilia and may contribute to various pregnancy complications such as venous thromboembolism (VTE), deep venous thrombosis (DVT), first trimester abortion, mid-trimester abortion, intrauterine fetal death, preeclampsia, placental abruption and fetal growth restriction [15]. The adequate fetomaternal circulating system is essential for normal development and function of the placenta [16]. It is obtained with a mechanism which prevents coagulation of the maternal blood around chorionic villas and fetal blood in them. Normal pathway in coagulation cascade includes the balance between procoagulants, anticoagulant and fibrinolytic components in the blood [17]. Depending on of the type of inherited thrombophilia, there is impaired neutralization of thrombin or failure to control the generation of thrombin. This will cause malfunction of natural anticoagulants that maintain the fluidity of the blood [18]. Coagulation factor (FV) is a large glycoprotein that is produced in the liver and circulates in plasma as a single-chain inactive precursor. After limited proteolysis by thrombin or FXa, FV is converted to its active form (FVa), which acts as an essential non-enzymatic cofactor of FXain prothrombin activation [19].

FVa is inactivated by activated protein C (APC) via proteolytic cleavage at Arg306, Arg506, and Arg679. Although Arg506 is the kinetically preferred APC-cleavage site, cleavage at Arg306 is required for complete loss of cofactor activity. Therefore, FVa is mainly inactivated via initial cleavage at Arg506 which

yields an intermediate 40% activity followed by slow cleavage at Arg306 [20]. However, FVa can also be inactivated by a single slow cleavage at Arg306 [21].

Recurrent miscarriage is a significant clinical problem of different etiologies [21]. Certain thrombophilic gene mutations have been associated with an increased risk of recurrent miscarriage [22]. Also mutations in Folate-related genes can lead to abnormal chromosomal segregation during meiosis which is the most common cause of recurrent miscarriage. We have developed a multiplex single-base extension reaction assay that allows simultaneous analysis of 10 different mutations in thrombophilia and folate related genes (Factor V Leiden G1691A), (Factor V H1299R), (Factor II G20210A), (Factor XIII V34L), (PAI-I -675 4G/5G), (FGB -455G/A), (MTHFR C677T, MTHFR A1298C), (MTR A2756G, and MTRR A66G) [23]. The purpose of this study is to check the common mutations in women with recurrent miscarriage. Furthermore, the study wants to scrutinize the relationship between common mutations and novel mutations.

Materials and Methods

Subjects and DNA extraction

A cohort of patients (100 women) with a history of two or more miscarriage up to 20 weeks was conducted at our laboratory between 2017 to 2018 in Tehran, Iran. This study included couples with repeated pregnancy losses who had presented themselves during this period for further investigations. Pregnancy was confirmed by a positive human chorionic gonadotropin test using serum or urine in

combination. In this study, the corresponding genes including F5 Leiden, F2, MTHFR-A, MTHFR-C, PAI 1, FGB and F13 were sequenced with sequencer device. Primers designed in this study are listed in table 1. Informed written consent was taken from each participant and a specific questionnaire was filled out by them. Blood samples were collected using 5 ml syringe. DNA Extraction was performed from ethylenediaminetetraacetic acid blood by using Gene All DNA Extraction kit (Cat No: 105-152, Korea). The quality and quantity of the samples were assessed by DeNovix DS-11 Spectrophotometer (DeNovix Technologies, USA) [24]. DNA extracted after purification (Sigma/Cat. No. 11732 668001) was obtained around 1.82- 1.95 with a suitable concentration. Finally DNA extracted with the final volume 50 µl was stored at -20°C.

Polymerase chain reaction and Sequencing

Primers for polymerase chain reaction (PCR) were designed by Gene Runner software (version 3.05) and their specificity for PCR was checked by nucleotide BLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) [25].

After DNA extraction, the PCR was performed with specific primer (Table 1).

The Optimum annealing temperature of all primers was set at 58-60°C. PCR reactions were performed in 20 µl total volume by specific primers for 100 samples. The reaction mixture contained 10 pM of each primer, PCR Master mix containing 1 unit of Taq DNA polymerase, 0.2 mM of each of dNTPs, 1.5 mM of MgCl₂ and 200 ng of DNA as template. All PCR reaction components were obtained from Fermentas Company. The amplification program was as follows: initial denaturation at 94°C for 4 min, followed by 35 cycles of denaturation at 94°C for 25 s, annealing at 58-60°C for 30 s and extension at 72°C for 2 min and an additional final extension at 72°C for 5 min. PCR products were analyzed by 1% agarose gel electrophoresis. The PCR products were run in gel electrophoresis and then were subjected to PCR product gel purification. The purified PCR products were sequenced for finding common mutations.

Table 1. The sequencing of primers that used in this study

Name	Primers	PCR Product (bp)
MTHFR-A-F*	CTTCTACCTGAAGAGCAAGTC	198
MTHFR-A-R**	CATGTCCACAGCATGGAG	
MTHFR-C-F	TGAAGGAGAAGGTGTCTGCGGGA	256
MTHFR-C-R	AGGACGGTGCGGTGAGAGTG	
F2-F	TCTAGAAACAGTTGCCTGGC	345
F2-R	ATAGCACTGGGAGCATTGAGGC	
F5-F	TGCCAGTGCTTAACAAGACCA	595
F5-R	TGTTATCACACTGGTGCTAA	
F13-F	GGCAAAATGTGTTGCTCAAG	484
F13-R	AGAACTGGGACAAGGCTCTG	
PAI1-F	CACAGAGAGAGTCTGGACACGTG	220
PAI1-R	TGCAGCCAGCCACGTGATTGTCTAG	
FGB-F	TGGGAAATGAAGGAAAATGG	504
FGB-R	TGACCTACTCACAAGGCAACC	

*Forward primer

**Reverse primer

Results

The frequencies were as follows: in the group with preeclampsia 50% were MTHFR gene thus containing homozygous and heterozygous mutation; 30% was found in MTHFR (A1298C) and 20% was identified in MTHFR (C677T). Then F2 (G20210A) and F5 Leiden (G1691A or R506Q) were aligned with 20% frequency. After that, PAI 1(-675 4G/5G) had a low frequency of about 5% and eventually, F13 (V34L or G100T) and FGB (-455 G>A) had the lowest frequency of about 2.5%. According to the results obtained, MTHFR has

the highest value for analyzing in recurrent miscarriage fetus. As a result, most women with recurrent miscarriage of the fetus have heterozygous mutations in the MTHFR gene. Moreover, many homozygous mutations in this gene were observed. In the following, common heterozygous mutations in these genes are visible (Table 2 and Fig. 1). In addition, the percentages of heterozygote and homozygote for mutations in MTHFR, F2 and F5 Leiden, being the most frequent among the studied subjects, are illustrated in table 3.

Table 2. Prevalence of common mutations in Iranian patients with miscarriage abortions

Mutations	N = %	P-value	OR (CI 95%)
A1298C (MTHFR)	30	0.001	8.16 (1.62-36.49)
C677T (MTHFR)	20	0.001	7.14 (1.53-33.97)
G20210A (F2)	20	0.6	1.79 (0.16- 36.49)
G1691A or R506Q (F5 Leiden)	20	0.07	2.09 (0.42- 32.86)
(- 675 4G/5G (PAI 1)	5	1	NS*
V34L or G100T (F13)	>2.5	NS	NS
- 455 G>A (FGB)	>2.5	NS	NS

*Not significant

Table 3. The percentages of heterozygote and homozygote for each mutation

Mutations names	Normal (N = %)	Hetrozygous (N = %)	Homozygous (N = %)
A1298C(MTHFR)	60	30	10
C677T (MTHFR)	72	20	8
G20210A (F2)	64	20	16
G1691A or R506Q (F5 Leiden)	48	20	32




Fig 1. A and B both belong to the results of sequence of the gene MTHFR by reverse primers, which indicate the conversion of A>C and C>T respectively. In both cases, the mutant is heterozygous. In figure C, a mutation in the F2 gene is shown which is marked with a flash of heterozygote mutation. The type of mutation in figure D identified belongs to F5 gene. This mutation is homozygous and G>A. Moreover, E and F respectively belong to the results of sequence of the gene PAI and F13, which indicate the heterozygous mutant.

Discussion

The development of venous thrombosis is generally considered to involve in a combination of local regional and systemic prothrombogenic factors [23]. Portomesenteric vein thrombosis (PMVT) is an uncommon but potentially catastrophic clinical complication that may lead to intestinal ischemia and infarction [26]. The etiology of PMVT complication following laparoscopic surgery is likely multifactorial. Some factors that may contribute to the pathogenesis of this condition include undiagnosed thrombophilia, local

injury near the portal flow, surgical damage (including direct trauma leading to diminished blood flow), and oral contraceptive use, increased intra-abdominal pressure due to pneumoperitoneum and prolonged time in the reverse trendelenburg position [27]. In patients with thrombo-embolic events, inherited thrombophilia is suspected when the patient has recurrent or life-threatening venous thromboembolism, family history of venous thrombosis, thrombo-embolic events in patients. The highest prevalence of F2

20210G <A mutation has been reported among the European Caucasus and the Mediterranean population living near Europe [28]. Furthermore, it was reported that the double heterozygotes had thrombosis at a significantly younger age compared to the rest [3]. Other than FV Leiden, another mutation F2 19911A>G found in the same gene has also been described as a risk factor which slightly increases the risk of venous thrombosis when co-existing with the F2 (20210G>A) mutation [5]. Rai and colleagues reported that there is no increase in mutation rates in coagulation factor 5 compared with healthy subjects. In this study, the 20% mutation prevalence in the population studied was related to this mutation [29].

Studies conducted among different racial groups have confirmed varying prevalences of the individuals with F2 20210G>A mutation [8]. The highest prevalence of F2 20210G>A mutation has been reported among Caucasians of European origin and Mediterranean populations living close to Europe [11]. Furthermore, the prevalence of the mutation in these populations is higher among patients with thrombo-embolic disorders compared with healthy controls [26]. However, in many Asian countries it is reported to be absent in both the healthy controls as well as the patients with thrombo-embolic disorders [21]. In 2009, a study was conducted by Dissanayake et al. to determine the F2 20210G>A mutant allele frequency among healthy controls in the Sri Lankan population. They reported that the mutation was absent among healthy controls across all the three ethnic groups (Sinhala,

Tamil and Moor) in Sri Lanka [30]. The present study was undertaken to determine the prevalence of the F2, 20210G>A mutation among Sri Lankan patients with thromboembolic disorders [9, 30]. In contrast to most reports from other Asian populations, we found that the mutation was not entirely absent among these patients as 0.8 % were heterozygotes for the mutation with a mutant allele frequency of 0.4 % [28].

Some of the individual studies have detected an increased risk of pregnancy loss in Indian, Turkish, and the Tunisian population with 1298AC and 1298 CC polymorphisms [31-33]. Mean plasma homocysteine was elevated among 1298AA homozygotes as compared with 1298C allele and was associated with recurrent pregnancy loss [34]. MTHFR 1298 AC genotype allele increased the risk of spontaneous abortion along with MTHFR-C677T [35]. In this study, the frequency of MTHFR gene was 50% so that 30% was found in MTHFR (A1298C) and 20% was identified in MTHFR (C677T). Base on our result, this mutation was higher than the other common mutation in thrombophilia.

Conclusion

In this study, the frequency of mutant allele of the gene MTHFR has a slightly higher percentage than others. According to the findings, mutations in the MTHFR gene in women with abortion that have no physical problems and no disease in holding a fetus in the womb, has been assessed. Concluding from the study, gene MTHFR and F5 are most pathogenic in recurrent miscarriage fetus, so it

can be referred to as very important genetic mutagenesis. In relation to MTHFR gene mutagenesis and F2, it can be concluded that these two genes may also be involved in recurrent miscarriage of the fetus.

References

- [1]. Leistra-Leistra M, Timmer A, Van Spronsen F, Geven W, Van der Meer J, Erwich J. Fetal thrombotic vasculopathy in the placenta: a thrombophilic connection between pregnancy complications and neonatal thrombosis? *Placenta* 2004; 25(Suppl A): S102-5.
- [2]. Chisholm KM, Heerema-McKenney A. Fetal thrombotic vasculopathy: significance in liveborn children using proposed society for pediatric pathology diagnostic criteria. *Am J Surg Pathol*. 2015; 39(2): 274-80.
- [3]. Stanek J, Sheridan R, Le L, Crombleholme T. Placental fetal thrombotic vasculopathy in severe congenital anomalies prompting EXIT procedure. *Placenta* 2011; 32(5): 373-79.
- [4]. Lian DW, Lam JC, Aung ACL, Li FX, Chang KT. Intestinal atresia occurring in association with placental fetal thrombotic vasculopathy: a case report with literature review. *Pediatr Dev Pathol*. 2013; 16(1): 28-31.
- [5]. Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. *Am J Reprod Immunol*. 2006; 55(5): 360-68.
- [6]. Aracic N, Roje D, Drmic Hofman I, Capkun V, Stefanovic V. Low molecular weight heparin treatment and impact of inherited thrombophilia type in pregnancies with previous adverse outcome. *J Maternal-Fetal Neonatal Med*. 2015; 28(3): 306-10.
- [7]. Crowther M, Lim W. Use of low molecular weight heparins in patients with renal failure; time to re-evaluate our preconceptions. *J Gen Intern Med*. 2016; 31(2): 147-48.
- [8]. Jacobsen A, Dahm A, Bergrem A, Jacobsen E, Sandset P. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. *J Thrombos Haemostas*. 2010; 8(11): 2443-449.
- [9]. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome?: A systematic review. *Euro J Obstet Gynecol Reprod Biol*. 2002; 101(1): 6-14.
- [10]. Croles F, Nasserinejad K, Duvekot J, Kruip M, Meijer K, Leebeek F. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian Meta-Analysis. *J Vascul Surg: Venous Lymph Disord*. 2018; 6(2): 280-88.
- [11]. Facchinetti F, Marozio L, Frusca T, Grandone E, Venturini P, Tiscia GL, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. *Am J Obstetrics Gynecol*. 2009; 200(1): 1-5.
- [12]. Prüller F, Raggam RB, Mangge H, Truschnig-Wilders M, Matzhold EM, Weiss EC, et al. A novel factor V mutation causes a normal activated protein C ratio despite the presence of a heterozygous F 5 R 506 Q (factor VL eiden) mutation. *Br J Haematol*. 2013; 163(3): 414-17.
- [13]. Livrinova V, Lega MH, Dimcheva AH, Samardziski I, Isjanovska R. Factor V leiden, prothrombin and MTHFR mutation in patients with preeclampsia, intrauterine growth restriction and placental abruption. *Macedonian J Med Sci*. 2015; 3(4): 590-94.
- [14]. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. *New Eng J Med*. 2001; 344(16): 1222-231.
- [15]. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. *Haematologica* 2002; 87(10): 1095-108.
- [16]. Segers O, Simioni P, Tormene D, Bulato C, Gavasso S, Rosing J, et al. Genetic modulation of the FVLeiden/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. *J Thrombos Haemostas*. 2012; 10(1): 73-80.
- [17]. Zakrzewski M, Zakrzewska E, Kiciński P, Przybylska-Kuć S, Dybała A, Myśliński W, et al. Evaluation of fibrinolytic inhibitors: alpha-2-antiplasmin and plasminogen activator inhibitor 1 in patients with obstructive sleep apnoea. *PLoS one* 2016; 11(11): e0166725.
- [18]. Martin-Fernandez L, Ziyatdinov A, Carrasco M, Millon JA, Martinez-Perez A, Vilalta N, et al. Genetic determinants of thrombin generation and their relation to venous thrombosis: results from

Conflict of Interest

The authors have no financial conflict of interest.

Acknowledgment

The authors sincerely appreciate of all the patients who participated in this study.

- the GAIT-2 project. *PloS one* 2016; 11(1): e0146922.
- [19]. Madjunkova S, Volk M, Peterlin B, Plaseska-Karanfilska D. Detection of thrombophilic mutations related to spontaneous abortions by a multiplex SNaPshot method. *Gen Test Mol Biomark.* 2012; 16(4): 259-64.
- [20]. Shen MC, Wu WJ, Cheng PJ, Ma GC, Li WC, Liou JD, et al. Low-molecular-weight-heparin can benefit women with recurrent pregnancy loss and sole protein S deficiency: a historical control cohort study from Taiwan. *Thromb J.* 2016; 14(1): 44.
- [21]. Miyata T, Maruyama K, Banno F, Neki R. Thrombophilia in East Asian countries: are there any genetic differences in these countries? *Thromb J.* 2016; 14(1): 25.
- [22]. Turki RF, Assidi M, Banni HA, Zahed HA, Karim S, Schulten HJ, et al. Associations of recurrent miscarriages with chromosomal abnormalities, thrombophilia allelic polymorphisms and/or consanguinity in Saudi Arabia. *BMC Med Gen.* 2016; 17(1): 69.
- [23]. Mazhari R, Mirfakhraie R, Asadi M, Olyaei NA, Kheiri H, Moslemi E, et al. Comparison of insulin expression levels in white blood cells of infants with and without family history of Type II diabetes. *Novel Biomed.* 2016; 4(4): 173-80.
- [24]. Ghasemi Z, Hashemi M, Ejabati M, Ebrahimi SM, Manjili HK, Sharafi A, et al. Development of a high-resolution melting analysis method for CYP2C19* 17 genotyping in healthy volunteers. *Avicenna J Med Biotech.* 2016; 8(4): 193-99.
- [25]. Poorhosseini S, Hashemi M, Alipour NO, Izadi A, Moslemi E, Ravesh Z, et al. New gene profiling in determination of breast cancer recurrence and prognosis in iranian women. *Asian Pacific Journal of Cancer Prevention: APJCP.* 2016; 17(S3): 155-60.
- [26]. Kacprzak M, Chrzanowska M, Skoczylas B, Moczulska H, Borowiec M, Sieroszewski P. Genetic causes of recurrent miscarriages. *Ginekologia Polska* 2016; 87(10): 722-26.
- [27]. Gunathilake K, Nisansala P, Goonasekera H, Jayasekara R, Dissanayake V. The prevalence of the prothrombin (F2) 20210G> A mutation in a cohort of Sri Lankan patients with thromboembolic disorders. *India J Hematol Blood Transfu.* 2015; 31(3): 356-61.
- [28]. Villagrán R, Smith G, Rodriguez W, Flores C, Cariaga M, Araya S, et al. Portomesenteric vein thrombosis after laparoscopic sleeve gastrectomy: incidence, analysis and follow-up in 1236 consecutive cases. *Obes Surg.* 2016; 26(11): 2555-561.
- [29]. Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marriott K, et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. *Human Reprod.* 2001; 16(5): 961-65.
- [30]. Dissanayake VH, Weerasekera LY, Gammulla CG, Jayasekara RW. Prevalence of genetic thrombophilic polymorphisms in the Sri Lankan population-implications for association study design and clinical genetic testing services. *Exp Mol Pathol.* 2009; 87(2): 159-62.
- [31]. Fan Y, Huang ZY, Cao CC, Chen CS, Chen YX, Fan DD, et al. Genome of the Chinese tree shrew. *Nature Commun.* 2013; 4(1): 1426.
- [32]. Nair RR, Khanna A, Singh R, Singh K. Association of maternal and fetal MTHFR A1298C polymorphism with the risk of pregnancy loss: a study of an Indian population and a meta-analysis. *Fertil Steril.* 2013; 99(5): 1311-318.
- [33]. Zonouzi A, Chaparzadeh N, Estiar M, Sadaghiani M, Farzadi L, Ghasemzadeh A, et al. Methylenetetrahydrofolate reductase C677T and A1298C mutations in women with recurrent spontaneous abortions in the northwest of Iran. *ISRN Obstetric Gynecol.* 2012; 86(1): 248249.
- [34]. Balasubramaniam A, Kotalawala S, Amarasekara R. Analysis of methylenetetrahydrofolate reductase (MTHFR) Polymorphisms (C677t & A1298c) in recurrent pregnancy loss (RPL). *J Gynecol.* 2017; 1(4): 1-5.
- [35]. del Rosario Rodríguez-Guillén M, Torres-Sánchez L, Chen J, Galván-Portillo M, Blanco-Muñoz J, Anaya MA, et al. Maternal MTHFR polymorphisms and risk of spontaneous abortion. *salud pública de méxico.* 2009; 51(1): 19-25.